Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
A0A3B3IT33

UPID:
TR51G_HUMAN

ALTERNATIVE NAMES:
Tripartite motif-containing 51G pseudogene

ALTERNATIVE UPACC:
A0A3B3IT33

BACKGROUND:
Putative tripartite motif-containing protein 51G, alternatively known as Tripartite motif-containing 51G pseudogene, is a fascinating protein encoded by the human genome. The protein's affiliation with the tripartite motif (TRIM) family, which plays pivotal roles in cell regulation, immune response, and other critical biological functions, underscores its potential importance in cellular mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions and mechanisms of Putative tripartite motif-containing protein 51G could unveil new therapeutic avenues. Given its connection to the TRIM protein family, it may be involved in pathways that are crucial for understanding disease mechanisms and developing innovative treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.